This is an old revision of this page, as edited by Whywhenwhohow (talk | contribs) at 04:40, 17 December 2024 (create). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 04:40, 17 December 2024 by Whywhenwhohow (talk | contribs) (create)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) MedicationPharmaceutical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | PD-L1 |
| Clinical data | |
| Trade names | Unloxcyt |
| Other names | CK-301, TG-1501, cosibelimab-ipdl |
| License data |
|
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6388H9912N1716O2032S44 |
| Molar mass | 144674.18 g·mol |
Cosibelimab, sold under the brand name Unloxcyt, is a monoclonal antibody used for the treatment of cutaneous squamous cell carcinoma. It is a programmed death ligand-1 (PD-L1) blocking antibody.
The most common adverse reactions include fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritis, edema, localized infection, and urinary tract infection.
Cosibelimab was approved for medical use in the United States in December 2024.
Medical uses
Cosibelimab is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
History
Efficacy was evaluated in study CK-301-101 (NCT03212404), a multicenter, multicohort, open-label trial in 109 participants with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who were not candidates for curative surgery or curative radiation. Participants were excluded if they had any of the following: active or suspected autoimmune disease, allogeneic transplant within six months prior to treatment, prior treatment with anti-PD-1/PD-L1 blocking antibodies or other immune checkpoint inhibitor therapy, uncontrolled or significant cardiovascular disease, ECOG PS • 2, or infection with HIV, hepatitis B, or hepatitis C.
Society and culture
Legal status
Cosibelimab was approved for medical use in the United States in December 2024.
Names
Cosibelimab is the international nonproprietary name.
Cosibelimab is sold under the brand name Unloxcyt.
References
- ^ https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761297s000lbl.pdf
- ^ "FDA approves cosibelimab-ipdl". U.S. Food and Drug Administration (FDA). 13 December 2024. Retrieved 17 December 2024.
This article incorporates text from this source, which is in the public domain.
- "Checkpoint Therapeutics Announces FDA Approval of Unloxcyt (cosibelimab-ipdl)". Checkpoint Therapeutics (Press release). 13 December 2024. Retrieved 17 December 2024.
- World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
External links
- "Cosibelimab-ipdl". NCI Drug Dictionary.
- "Cosibelimab (Code C151947)". NCI Thesaurus.
- Clinical trial number NCT03212404 for "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers" at ClinicalTrials.gov
| Monoclonal antibodies for tumors | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor |
| ||||||||||||
| |||||||||||||
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |